Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
doi 10.1093/ibd/izae250 101 GorelikYGhersinILujanRShlonDLoewenberg WeisbandYBen-TovAet al
C.Janssen-HeiningerY
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al
A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM
US$ 24.82
US$ 23.42
US$ 26.56
US$ 24.31
